GlassScriptPhysician profile
David L Speizman
NPI 1952356685
$4,111.66
in general payments reported to CMS, 2019-2025
31 companies · $832 in 2025
The $832 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $545 · 2021: $721 · 2022: $532 · 2023: $474 · 2024: $631 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $597.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $394.64 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $311.74 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $301.86 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $271.60 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $246.43 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $225.58 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $217.37 | 2019-2024 | Livalo |
| Exact Sciences Corporation | $198.24 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $155.85 | 2020-2025 | |
| Esperion Therapeutics, INC. | $136.53 | 2021-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $131.86 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.71 | 2021-2025 | |
| Abbvie INC. | $115.37 | 2021-2024 | |
| Astellas Pharma US INC | $104.66 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $88.62 | 2019-2025 | |
| Lilly USA, LLC | $77.66 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $67.83 | 2019-2025 | Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $60.86 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $46.89 | 2022-2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.68 | 2020-2024 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $31.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.85 | 2019 | |
| Ibsa Pharma INC. | $22.26 | 2024 | Licart, Tirosint |
| Daiichi Sankyo INC. | $21.92 | 2020 | |
| Eisai INC. | $21.51 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.68 | 2022 | |
| Sumitomo Pharma America, INC. | $18.93 | 2023 | Gemtesa |
| Mannkind Corporation | $18.50 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.80 | 2025 | Onpattro |
| Lundbeck LLC | $13.68 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Speizman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.